Collaborations are a cornerstone of our business model and success. Since our inception, we have been working together with leading research and development institutions and companies around the world.
Keyzilen® is being developed by Auris Medical based on a research collaboration and licensing agreement with Inserm.
AM-111 is being developed by Auris Medical based on an exclusive license and collaboration agreement concluded with Xigen for applications in the area of ear disorders.
Auris Medical is collaborating with King's College London on the discovery of small molecule compounds for a second generation tinnitus treatment, AM-102.